Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Aurora Spine Corp
Bactech Environmental Crp
Biote Corp. - Class A common stock
Black Titan Corp - Ordinary Shares
Castellum, Inc. Common Stock
Cobalt Blue Holdings Limited
DatChat, Inc. - Common Stock
Ecolomondo Corp
Edgewell Personal Care Company Common Stock
J & J Snack Foods Corp. - Common Stock
NEOS Boosted Bitcoin High Income ETF
Origin Agritech Limited - Ordinary Shares
Sable Offshore Corp. Common Stock
Sflmaven Corp
Yukon Metals Corp
iShares iBonds Dec 2026 Term Treasury ETF
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evommune, Inc. Common Stock
(NY:
EVMN
)
6.310
UNCHANGED
Delayed Quote
Updated: 7:00 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Evommune, Inc. Common Stock
Which stocks are experiencing notable movement on Monday?
↗
June 29, 2026
Via
Chartmill
What's going on in today's session
↗
June 29, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
June 29, 2026
Via
Chartmill
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
↗
June 08, 2026
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?
↗
February 10, 2026
Via
Stocktwits
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
↗
June 03, 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
↗
May 31, 2026
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
↗
March 10, 2026
Evommune has two autoimmune disorder treatments with blockbuster potential.
Via
The Motley Fool
The trading volume of these stocks is deviating from the norm in today's session.
↗
February 13, 2026
Via
Chartmill
On Wednesday, there are stocks with unusual volume. Let's take a look.
↗
February 11, 2026
Via
Chartmill
Top stock movements in today's session.
↗
February 10, 2026
Via
Chartmill
Here are the top movers in Tuesday's session.
↗
February 10, 2026
Via
Chartmill
These stocks are gapping in today's session
↗
February 10, 2026
Via
Chartmill
Top movers in Tuesday's pre-market session
↗
February 10, 2026
Via
Chartmill
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
↗
January 19, 2026
Via
MarketBeat
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.